Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement

GlobeNewswire October 19, 2022

Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

GlobeNewswire October 19, 2022

Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update

GlobeNewswire September 12, 2022

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

GlobeNewswire June 29, 2022

Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update

GlobeNewswire June 8, 2022

Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

GlobeNewswire June 3, 2022

Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

GlobeNewswire May 26, 2022

Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

GlobeNewswire April 27, 2022

Advaxis Announces Publication of ADXS-PSA Data in The Oncologist

GlobeNewswire April 8, 2022

ADXS Investor Alert - Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS

Business Wire March 28, 2022

Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update

GlobeNewswire March 17, 2022

Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update

GlobeNewswire February 14, 2022

Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement

GlobeNewswire January 28, 2022

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones

GlobeNewswire January 11, 2022

OTC Markets Group Welcomes Advaxis, Inc. to OTCQX

PR Newswire December 23, 2021

Advaxis Announces Acceptance for Trading on the OTCQX

GlobeNewswire December 22, 2021

Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value

GlobeNewswire December 17, 2021

Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results

GlobeNewswire December 9, 2021

Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting

GlobeNewswire November 24, 2021

Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements

GlobeNewswire November 22, 2021